News

SA hospital system’s nonprofit owner taps new CEO with close ties

Jaime Wesolowski is putting off retirement to become the new CEO of Methodist Healthcare Ministries of ...

StemBioSys CEO: Company has room to grow in San Antonio

Bob Hutchens is CEO of StemBioSys Inc. CARLOS JAVIER SANCHEZ | SABJ By W. Scott Bailey – Senior ...

Events

Medical Devices 101: An Educational Forum

When:  8:00 – 5:00 pm Monday, August 13 Where:  Norris Conference Center, ...
News
GenSpera enrolls first patient in cancer trial
January 28, 2010

GenSpera Inc. has reached a milestone in the development of its investigational cancer drug.

In a phase 1 clinical study, doctors at the University of Wisconsin Carbone Cancer Center in Madison treated the first patient with GenSpera’s cancer chemotherapeutic agent G-202.

The phase 1 clinical study is designed to treat up to 30 patients with cancers that have progressed even after treatment with other anti-cancer therapies. The study will determine the safety, tolerability and effect the drug has on the human body. Researchers will also study how effective the drug is in treating solid tumors.

G-202 is designed to target the blood vessels in solid tumors in order to destroy the tumor’s blood supply.

San Antonio-based GenSpera is a development stage oncology company.

Stay informed. Subscribe to BioMed SA news alerts.